Concepedia

Somak Chatterjee

SC

Statistics

Publications

6

Citations

282

H-Index

6

Active since

2021

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Center for Devices and Radiological Health

Somak Chatterjee is an author at United States Food and Drug Administration specializing in cancer therapeutics, lung cancer, and medicine.

ORCID

Top concepts

Publications per year

2021–2025

6

Publications

6

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <i>RET</i> Gene Mutations or Fusions

Janice Kim, Diana Bradford, Erin Larkins et al. · Clinical Cancer Research · 2021 · 99 citations

, , +16

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

Timil H. Patel, Leigh Marcus, M. Naomi Horiba et al. · Clinical Cancer Research · 2022 · 49 citations · Full text

FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations

Katie Chon, Erin Larkins, Somak Chatterjee et al. · Clinical Cancer Research · 2023 · 48 citations · Full text

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer

Elizabeth S. Duke, Amy Barone, Somak Chatterjee et al. · Clinical Cancer Research · 2022 · 44 citations · Full text

Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis

Bernardo H. L. Goulart, Sirisha L. Mushti, Somak Chatterjee et al. · The Lancet Oncology · 2024 · 31 citations

, , +8

1–5 of 6